In addition, multiple RCTs and observational studies examining the suppressive effect of the above SGLT2 inhibitors on renal events (Table 1) have shown that therapeutic drugs that reduce the eGFR slope by approximately 0.75–1.53 mL/min/1.73 m2/year in patients with early CKD reduce the risk of progression to clinical endpoints. The gene discussed is SLC5A2; the disease is chronic kidney disease.